WILSON TROY EDWARD — SEC insider filings
SEC reporting owner CIK 1589597. 46 insider filings on record with FilingPulse; latest filed 2026-11-17.
Transaction summary — filings shown
Covers all 46 filings on record, filed 2020-08-19 to 2026-11-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 9 legs across 6 filings — 700,000 shares, $6,073,876 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 35 legs across 16 filings — 958,031 shares, $25,365,910 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 84.
- Largest priced transaction: sale of 106,736 shares @ $34.00 ($3,629,024) in Kura Oncology, Inc., filed 2020-10-08.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Kura Oncology, Inc. (KURA) | President and CEO, Director | 24 | 9 legs · 700,000 sh · $6,073,876 | 20 legs · 699,271 sh · $18,905,937 | 54 |
| Avidity Biosciences, Inc. (RNAM) | Director | 10 | — | 8 legs · 124,554 sh · $5,752,430 | 23 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | Director | 11 | — | 7 legs · 134,206 sh · $707,543 | 6 |
| Atrium Therapeutics, Inc. (RNA) | Director | 1 | — | — | 1 |
Insider filings — WILSON TROY EDWARD
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-17 | 4/A | Kura Oncology, Inc. (KURA) | Purchase (P): 98,881 @ $7.63 · Purchase (P): 101,119 @ $7.42 | EDGAR |
| 2026-11-16 | 4 | Kura Oncology, Inc. (KURA) | Purchase (P): 98,881 @ $7.63 · Purchase (P): 101,119 @ $7.42 | EDGAR |
| 2026-09-16 | 4 | PUMA BIOTECHNOLOGY, INC. (PBYI) | Sale (S): 5,000 @ $9.10 | EDGAR |
| 2026-08-24 | 4 | Kura Oncology, Inc. (KURA) | Purchase (P): 100,000 @ $12.39 | EDGAR |
| 2026-08-17 | 4 | Kura Oncology, Inc. (KURA) | Purchase (P): 100,000 @ $11.12 | EDGAR |
| 2026-06-15 | 4 | PUMA BIOTECHNOLOGY, INC. (PBYI) | Grant/award (A): 27,000 @ $0 · Sale (S): 10,800 @ $7.20 | EDGAR |
| 2026-03-25 | 4 | Kura Oncology, Inc. (KURA) | Option exercise (M): 6,103 @ $6.15 · Option exercise (M): 6,103 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Atrium Therapeutics, Inc. (RNA) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-02-27 | 4 | Avidity Biosciences, Inc. (RNAM) | Disposition to issuer (D): 65,091 · Disposition to issuer (D): 13,711 · Disposition to issuer (D): 10,034 (derivative) · Disposition to issuer (D): 13,489 (derivative) · Disposition to issuer (D): 15,000 (derivative) | EDGAR |
| 2026-01-06 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 1,120,000 (derivative) @ $0 | EDGAR |
| 2025-11-14 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 182,500 @ $0 | EDGAR |
| 2025-09-29 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 182,500 @ $0 · Sale (S): 36,615 @ $8.94 | EDGAR |
| 2025-09-09 | 4 | Kura Oncology, Inc. (KURA) | Purchase (P): 50,000 @ $8.20 | EDGAR |
| 2025-09-09 | 4 | Avidity Biosciences, Inc. (RNA) | Option exercise (M): 14,500 @ $12.48 · Sale (S): 14,500 @ $50 · Sale (S): 15,000 @ $50 · Option exercise (M): 14,500 (derivative) @ $0 | EDGAR |
| 2025-08-14 | 4 | Kura Oncology, Inc. (KURA) | Purchase (P): 36,506 @ $5.85 · Purchase (P): 13,494 @ $6.64 | EDGAR |
| 2025-08-08 | 4 | Avidity Biosciences, Inc. (RNA) | Option exercise (M): 22,000 @ $12.03 · Sale (S): 22,000 @ $45 · Option exercise (M): 7,500 @ $12.48 · Sale (S): 7,500 @ $45 · Sale (S): 15,000 @ $45 · Sale (S): 15,000 @ $45 · +4 more | EDGAR |
| 2025-06-17 | 4 | PUMA BIOTECHNOLOGY, INC. (PBYI) | Sale (S): 10,800 @ $3.40 | EDGAR |
| 2025-06-13 | 4 | PUMA BIOTECHNOLOGY, INC. (PBYI) | Grant/award (A): 27,000 @ $0 | EDGAR |
| 2025-06-12 | 4 | Avidity Biosciences, Inc. (RNA) | Grant/award (A): 6,692 @ $0 · Grant/award (A): 10,034 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 625,000 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | PUMA BIOTECHNOLOGY, INC. (PBYI) | Grant/award (A): 27,000 @ $0 | EDGAR |
| 2024-06-17 | 4 | PUMA BIOTECHNOLOGY, INC. (PBYI) | Sale (S): 27,000 @ $3.33 | EDGAR |
| 2024-06-14 | 4 | Avidity Biosciences, Inc. (RNA) | Grant/award (A): 13,489 (derivative) @ $0 | EDGAR |
| 2024-01-26 | 4 | Kura Oncology, Inc. (KURA) | Option exercise (M): 6,945 @ $4.80 · Sale (S): 6,945 @ $20.23 · Option exercise (M): 84,107 @ $6.15 · Sale (S): 84,107 @ $20.23 | EDGAR |
| 2024-01-04 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 560,000 (derivative) @ $0 | EDGAR |
| 2023-12-14 | 4 | Avidity Biosciences, Inc. (RNA) | Other (J): 300,000 @ $0 · Other (J): 300,000 @ $0 · Other (J): 250,000 @ $0 · Other (J): 250,000 @ $0 | EDGAR |
| 2023-12-11 | 4 | Kura Oncology, Inc. (KURA) | Gift (G): 2,000 @ $0 · Gift (G): 1,000 @ $0 | EDGAR |
| 2023-06-20 | 4 | Avidity Biosciences, Inc. (RNA) | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | PUMA BIOTECHNOLOGY, INC. (PBYI) | Sale (S): 27,000 @ $3.45 · Grant/award (A): 27,000 @ $0 | EDGAR |
| 2023-06-02 | 4 | Kura Oncology, Inc. (KURA) | Other (J): 8,394 @ $0 · Other (J): 8,394 @ $0 · Other (J): 41,318 @ $0 · Other (J): 212,500 @ $0 · Other (J): 300,000 @ $0 · Other (J): 300,000 @ $0 · +2 more | EDGAR |
| 2023-02-21 | 4 | Kura Oncology, Inc. (KURA) | Other (J): 468,297 @ $0 · Other (J): 17,708 @ $0 · Other (J): 41,318 @ $0 · Other (J): 41,318 @ $0 · Other (J): 1,084,300 @ $0 · Other (J): 1,084,300 @ $0 · +2 more | EDGAR |
| 2022-06-21 | 4 | PUMA BIOTECHNOLOGY, INC. (PBYI) | Sale (S): 27,858 @ $2.58 | EDGAR |
| 2022-06-17 | 4 | Avidity Biosciences, Inc. (RNA) | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2022-06-16 | 4 | PUMA BIOTECHNOLOGY, INC. (PBYI) | Grant/award (A): 27,000 @ $0 | EDGAR |
| 2022-01-28 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 495,000 (derivative) @ $0 | EDGAR |
| 2021-06-17 | 4 | PUMA BIOTECHNOLOGY, INC. (PBYI) | Grant/award (A): 27,858 @ $0 | EDGAR |
| 2021-06-16 | 4 | Avidity Biosciences, Inc. (RNA) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2021-06-11 | 4 | PUMA BIOTECHNOLOGY, INC. (PBYI) | Sale (S): 25,748 @ $11.36 | EDGAR |
| 2021-01-28 | 4 | Kura Oncology, Inc. (KURA) | Other (J): 175,000 @ $0 · Grant/award (A): 366,500 (derivative) @ $0 | EDGAR |
| 2020-12-28 | 4 | Avidity Biosciences, Inc. (RNA) | Other (J): 100,000 @ $0 · Other (J): 100,000 @ $0 | EDGAR |
| 2020-12-02 | 4 | Kura Oncology, Inc. (KURA) | Option exercise (M): 11,855 @ $6.15 · Option exercise (M): 11,855 (derivative) @ $0 | EDGAR |
| 2020-10-08 | 4 | Kura Oncology, Inc. (KURA) | Sale (S): 100 @ $32 · Sale (S): 99,900 @ $32 · Sale (S): 106,736 @ $34 · Option exercise (M): 4,586 @ $6.15 · Sale (S): 4,586 @ $34 · Option exercise (M): 50,370 @ $6.15 · +3 more | EDGAR |
| 2020-09-15 | 4 | Kura Oncology, Inc. (KURA) | Option exercise (M): 17,926 @ $6.15 · Sale (S): 17,926 @ $28 · Sale (S): 485 @ $28 · Sale (S): 98,490 @ $28.82 · Option exercise (M): 17,926 (derivative) @ $0 | EDGAR |
| 2020-09-10 | 4 | Kura Oncology, Inc. (KURA) | Sale (S): 50,000 @ $26 · Sale (S): 1,025 @ $28 · Option exercise (M): 37,030 @ $6.15 · Sale (S): 37,030 @ $28 · Option exercise (M): 37,030 (derivative) @ $0 | EDGAR |
| 2020-08-26 | 4 | Kura Oncology, Inc. (KURA) | Option exercise (M): 6,568 @ $4.80 · Sale (S): 6,568 @ $22.04 · Option exercise (M): 22,838 @ $6.15 · Option exercise (M): 215 @ $4.80 · Sale (S): 23,053 @ $22.37 · Option exercise (M): 6,568 (derivative) @ $0 · +2 more | EDGAR |
| 2020-08-19 | 4 | Kura Oncology, Inc. (KURA) | Gift (G): 26,041 @ $0 · Gift (G): 26,041 @ $0 · Sale (S): 50,000 @ $22 · Option exercise (M): 12,901 @ $4.80 · Sale (S): 12,901 @ $22.00 · Option exercise (M): 521 @ $4.80 · +6 more | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-18 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1589597 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs